Ypsomed Holding AG Q2 2027 Earnings Recap

Shares rose 10.8% after earnings, with investors responding to Ypsomed’s raised full-year guidance and a strong first half. New project wins and broad demand across therapeutic areas support the growth outlook, though management said autoinjectors are currently the clearest growth driver.

Key Takeaways

• Management raised full-year guidance, calling this the first guidance increase in Simon Michel’s 14 years as CEO; the transcript excerpt does not provide revised figures.
• Ypsomed won 30 new projects in the half year—more than two-thirds of the prior full-year total—and added 10 customers, bringing its customer base to 130.
• The company is active in close to 300 clinical and commercial programs: roughly 90 launched and 190 in development. The largest 10 customers account for about 50% of the portfolio.
• More than 70% of revenue comes from autoinjectors and roughly one-third from pens; management identified autoinjectors as the current growth driver.
• Management says pre-verification work has brought the time to prepare devices for clinical studies to below six months, with a target of three months.